LLY, MRK, PFE: Biopharma’s Back In 2024

Expect 2024 to be the year of gradual recovery for biopharmaceuticals, notes CFRA’s Sel Hardy. She and Jefferies’ Brian Tanquilut discuss health care trends to watch in 2024. Hardy mentions that oncology and diabetes will be the fastest growing therapy areas. Her top stock picks include Eli Lilly (LLY), Merck (MRK), and Pfizer (PFE). Tanquilut highlights that Jefferies continues to like HCA given the solid company fundamentals, reasonable valuation, and opportunity for earnings upside. Tune in to find out more about the stock market today.